查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117032

肺動脈栓塞治療市場：依治療方法、給藥途徑、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Pulmonary Embolism Therapeutics Market, By Treatment, By Route of Administration, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 354 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025年肺動脈栓塞治療市場價值為31.058億美元，預計從2026年到2033年將以6.6%的複合年成長率成長。

肺動脈栓塞的治療方法包括使用藥物降低血液凝固能力、使用溶栓劑清除血栓、進行血栓切除術、以及各種恢復肺部血流的手術。雖然藥物治療是肺動脈栓塞的標準治療方法，但由於中高風險患者數量不斷增加，機械取栓術和導管介入治療也正在被考慮。此外，醫院正在組成多學科肺動脈栓塞反應小組（PERT），以便評估和治療危及生命的肺動脈栓塞患者。 PERT聯盟2025年的一項研究納入了12346名患者，其中2958名接受了高級治療。這顯示肺動脈栓塞的治療方法正從統一的模式轉向基於患者需求的個人化模式。

肺動脈栓塞治療市場—市場動態

風險分層護理正在重塑治療選擇。

目前，治療強度的決定越來越傾向於基於患者的風險等級而非診斷結果。涉及急診醫學、循環系統、呼吸內科、血管內科和介入醫學的多學科協作模式正在建立，以便在識別出疾病進展高風險時，能夠提供替代治療方案或迅速獲得更強化的治療。Meta分析顯示，肺栓塞逆轉錄病毒療法（PERT）治療後的總體死亡率低於傳統治療，比值比為0.72，且先進治療方案的使用率也更高。這顯著影響了商業性格局，因為治療選擇現在很大程度上取決於導管技術、醫院規程、介入治療經驗、實證醫學證據和醫療網路。因此，肺動脈栓塞（PE）的協調管理是治療中至關重要的差異化因素。

肺動脈栓塞治療市場－市場區隔分析：

全球肺動脈栓塞治療市場按治療方法、給藥途徑、最終用戶和地區進行細分。

就終端用戶而言，醫院是主要組成部分。這是因為給藥途徑、風險因子分析、抗凝血治療啟動、溶栓治療、干涉導管、手術和重症監護通常需要高度協調的醫療程序。專科診所主要負責協調術後護理、監督抗凝血治療和居家照護，儘管居家照護更屬於急性後期治療方案，而非急性期治療方案。 2025年的一項院間轉診調查顯示，32.3%的轉診患者接受了導管操作，而直接從社區入院的患者中僅有17.1%接受了導管操作。這些數據表明，醫院服務範圍如何影響院間轉診模式。因此，終端用戶領域的競爭更取決於服務範圍和專業技術，而非醫療機構的總數。

肺動脈栓塞治療市場—區域分析

美國是肺動脈栓塞治療藥物研發領域成長最快的市場，這得益於其高度發展的心血管和介入醫療基礎設施，能夠開展機械取栓術和肺動脈栓塞（PE）的綜合治療等手術。美國擁有完善的醫療設備製造商、學術機構和醫療服務提供者基礎，以及促進實證醫學證據產生和商業化的監管和報銷體系。根據PERT聯盟2025年的一項註冊研究（涵蓋48家美國醫院和2958名接受創新技術治療的患者），美國臨床醫生持續積極參與關於醫療設備研發和應用的對話。因此，美國市場是目前用於肺動脈栓塞治療的各種醫療設備創新和交流的關鍵樞紐，需要多學科合作。

歐洲市場涵蓋眾多國家，各國的心臟醫療服務水準參差不齊。歐洲醫療體系的一個關鍵特徵是其分散的結構，包括高度專業化的醫院、覆蓋全國的醫療服務網路以及各具專長的心臟醫療服務機構。在歐洲，治療方案的選擇更取決於報銷政策、手術技術的可近性和臨床證據，而非醫療資源的可近性。根據2025年歐洲心臟學會（ESC）心血管統計報告，該報告分析了來自56個ESC成員國的數據，涵蓋超過9億名患者。由於醫療體系結構的複雜性，各國提供肺動脈栓塞（PE）治療服務的醫院數量可能有所不同。然而，歐洲各地的循環系統仍在利用創新技術提供高品質的醫療服務。總體而言，該地區治療方法多樣，這源自於醫院資源的分散性。

目錄

第1章：肺動脈栓塞治療市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：肺動脈栓塞治療藥物的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：肺動脈栓塞治療藥物的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：肺動脈栓塞治療市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：肺動脈栓塞

  • 肺動脈栓塞治療藥物市佔率分析（2025年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：肺動脈栓塞治療市場：依療法分類

  • 概述
    • 基於細分市場的市佔率分析：依治療方式分類
    • 直介面服抗凝血劑（DOACs）
    • 低分子量肝素（LMWH）
    • 未分級肝素
    • 維生素K拮抗劑
    • 溶栓藥物
    • 其他

第8章：肺動脈栓塞治療市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 口服
    • 注射藥物
    • 其他

第9章：肺動脈栓塞治療市場：依最終使用者分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 醫院
    • 專科診所
    • 零售藥房
    • 家庭醫療保健服務提供者
    • 其他

第10章：肺動脈栓塞治療市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第11章：主要供應商分析：肺動脈栓塞治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Bayer AG
    • Johnson & Johnson
    • Pfizer Inc.
    • Bristol Myers Squibb
    • Daiichi Sankyo Co., Ltd.
    • Sanofi
    • Boehringer Ingelheim
    • Viatris Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Amgen Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences Inc.
    • Takeda Pharmaceutical Company Limited
    • Others

第12章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7266

Pulmonary Embolism Therapeutics Market size was valued at US$ 3,105.8 Million in 2025, expanding at a CAGR of 6.6% from 2026 to 2033.

The treatment of pulmonary embolism includes the use of drugs to reduce the coagulation ability of blood, thrombolytics to remove the clot, clot removal procedures, and various surgeries to re-establish blood flow in the lungs. Medication is the standard treatment for pulmonary embolism, but mechanical thrombectomy and catheter-based treatments are being considered for a growing number of moderate and high-risk patients. Additionally, hospitals are starting to form multidisciplinary pulmonary embolism response teams that can assess and treat patients with life-threatening pulmonary embolism. The 2025 study by the PERT Consortium includes 12,346 patients, out of which 2,958 received advanced treatments. This shows that the treatment of pulmonary embolism is shifting from a standardized approach to a more individualized one, based on the patient's needs.

Pulmonary Embolism Therapeutics Market- Market Dynamics

Risk-Stratified Care Is Reshaping Treatment Selection

There is a growing trend towards determining the intensity of treatment based on the level of risk in patients, rather than diagnoses. Multidisciplinary response models that involve emergency medicine, cardiology, pulmonary, vascular, and interventional disciplines are being formed to provide alternative treatments and rapid access to more intensive therapies when a high likelihood of deterioration is detected. The meta-analysis performed in 2025, which included 24 studies, revealed that overall mortality after PERT treatment was lower compared to conventional care, with an odds ratio of 0.72 and a higher utilization of advanced therapies. Its impact on the commercial landscape is profound, since the choice of treatment now depends more on catheter technology, hospital protocols, interventional expertise, evidence generation, and networks. Thus, coordinated management of PE has become a significant differentiator in therapy.

Pulmonary Embolism Therapeutics Market- Segmentation Analysis:

The Global Pulmonary Embolism Therapeutics Market is segmented on the basis of Treatment, Route of Administration, End User, and Region.

In terms of End User, Hospitals account for the primary end-user segment, as the Route of Administration, risk-factor analysis, introduction of anticoagulant therapy, fibrinolytic treatment, interventional catheterization, surgery, and intensive care usually require highly coordinated medical procedures. Specialized clinics are mostly involved in aftercare coordination, anticoagulant supervision, and home care, while the latter is rather a post-acute option than an acute care choice. According to a 2025 interhospital transfer study, catheterization was implemented in 32.3% of transferred patients versus 17.1% of those who entered directly from the community. This data illustrates how the procedural scope of hospitals affects interfacility transfer patterns. Hence, the competition within the end-user segment is mainly conditioned by the range of operations and expertise rather than the overall number of facilities.

Pulmonary Embolism Therapeutics Market- Geographical Insights

The United States is the fastest growing market for developing treatments for pulmonary embolism due to its high level of development of cardiovascular and interventional infrastructures for such procedures as mechanical thrombectomy and coordinated treatment of PE. The US has a developed base of device companies, academic institutions, and care providers, as well as regulatory and reimbursement systems to improve evidence generation and commercialization. According to the PERT Consortium's 2025 registry study, which included 48 US hospitals and 2,958 patients who received therapy with innovative techniques, clinicians in the United States continue to engage in an active dialogue about the development and use of medical devices. Thus, the US market is an important center for innovation and interaction for various medical devices that require a multidisciplinary approach and are used in the current treatment of PE.

The European market includes a large number of countries with different levels of cardiological care provision. The main feature of the European healthcare system is its segmented structure, which includes highly specialized hospitals, networks of national care providers, and cardiological services with unique competencies. The choice of intervention method in Europe is associated with reimbursement policies, access to surgical techniques, and clinical evidence rather than availability. According to the 2025 ESC cardiovascular statistics report, the data from 56 member states of the European Society of Cardiology, representing more than 900 million patients, were analyzed. Due to the complex structure of the healthcare system, the number of hospitals providing services for treating PE may vary from country to country. However, cardiologists in individual European countries continue to provide high-quality care with innovative techniques. In general, this region is characterized by a wide range of approaches to treatment, which is due to the segmentation of the hospital base.

Pulmonary Embolism Therapeutics Market- Competitive Landscape:

Competitive positioning trends for thrombectomy catheters are shifting towards showcasing combinations of clinical evidence, procedural pathways, and institutional adoption capability rather than individual device characteristics. Stryker's vascular division secured a dominant position in the field across peripheral interventional devices with the 2025 acquisition of Inari Medical, which saw the FlowTriever pulmonary embolism (PE) retrieval system added to its product suite. Meanwhile, Penumbra is set to report findings from its multicenter registry study for computer-assisted vacuum thrombectomy. The FDA's 2025 record for Symphony-PE cites the inclusion of 109 patients at 19 US sites in a prospective study. Evidence, consistency of supply, physician training, and overall breadth of offerings are becoming key differentiating factors as the clinical, economic, and procedural complexities around peripheral and pulmonary thrombectomy interventions become more prominent.

Recent Developments:

In February 2025, Stryker completed the acquisition of Inari Medical. The deal merged FlowTriever, a pulmonary embolism mechanical thrombectomy platform, into Stryker's line, improving its peripheral vascular position and access to integrated venous thromboembolism technologies.

In June 2025, Penumbra completed recruitment for the STORM-PE randomized controlled trial. This multicenter trial enrolled 100 patients and was conducted by comparing computer-assisted vacuum thrombectomy with anticoagulation against anticoagulation alone, increasing the body of evidence supporting the mechanical treatment of PE.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Bayer AG
  • Johnson & Johnson
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Co., Ltd.
  • Sanofi
  • Boehringer Ingelheim
  • Viatris Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Takeda Pharmaceutical Company Limited
  • Others

GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY TREATMENT- MARKET ANALYSIS, 2020 - 2033

  • Direct Oral Anticoagulants (DOACs)
  • Low-Molecular-Weight Heparin (LMWH)
  • Unfractionated Heparin
  • Vitamin K Antagonists
  • Thrombolytics
  • Others

GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY ROUTE OF ADMINISTATION- MARKET ANALYSIS, 2020 - 2033

  • Oral
  • Injectables
  • Others

GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals
  • Specialty Clinics
  • Retail Pharmacies
  • Home Healthcare Providers
  • Others

GLOBAL PULMONARY EMBOLISM THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Pulmonary Embolism Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pulmonary Embolism Therapeutics Market Snippet by Treatment
    • 2.1.2. Pulmonary Embolism Therapeutics Market Snippet by Route of Administration
    • 2.1.3. Pulmonary Embolism Therapeutics Market Snippet by End User
    • 2.1.4. Pulmonary Embolism Therapeutics Market Snippet by Country
    • 2.1.5. Pulmonary Embolism Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Pulmonary Embolism Therapeutics Key Market Trends

  • 3.1. Pulmonary Embolism Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pulmonary Embolism Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pulmonary Embolism Therapeutics Market Opportunities
  • 3.4. Pulmonary Embolism Therapeutics Market Future Trends

4. Pulmonary Embolism Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pulmonary Embolism Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pulmonary Embolism Therapeutics Market Landscape

  • 6.1. Pulmonary Embolism Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pulmonary Embolism Therapeutics Market - By Treatment

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment, 2025 & 2033 (%)
    • 7.1.2. Direct Oral Anticoagulants (DOACs)
    • 7.1.3. Low-Molecular-Weight Heparin (LMWH)
    • 7.1.4. Unfractionated Heparin
    • 7.1.5. Vitamin K Antagonists
    • 7.1.6. Thrombolytics
    • 7.1.7. Others

8. Pulmonary Embolism Therapeutics Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectables
    • 8.1.4. Others

9. Pulmonary Embolism Therapeutics Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Specialty Clinics
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Home Healthcare Providers
    • 9.1.6. Others

10. Pulmonary Embolism Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pulmonary Embolism Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pulmonary Embolism Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.16. Denmark
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.16.3. Denmark Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.16.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.17. Rest of Europe
      • 10.3.17.1. Overview
      • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pulmonary Embolism Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.15. Taiwan
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.15.3. Taiwan Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.15.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.16. Vietnam
      • 10.4.16.1. Overview
      • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.16.3. Vietnam Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.16.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.17. Rest of APAC
      • 10.4.17.1. Overview
      • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.17.3. Rest of APAC Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Pulmonary Embolism Therapeutics Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Pulmonary Embolism Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.13. Iran
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.13.3. Iran Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.13.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.14. Qatar
      • 10.6.14.1. Overview
      • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.14.3. Qatar Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.14.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.15. Rest of MEA
      • 10.6.15.1. Overview
      • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.15.3. Rest of MEA Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
      • 10.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Pulmonary Embolism Therapeutics Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Bayer AG
    • 11.2.2. Johnson & Johnson
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Bristol Myers Squibb
    • 11.2.5. Daiichi Sankyo Co., Ltd.
    • 11.2.6. Sanofi
    • 11.2.7. Boehringer Ingelheim
    • 11.2.8. Viatris Inc.
    • 11.2.9. Novartis AG
    • 11.2.10. Eli Lilly and Company
    • 11.2.11. Amgen Inc.
    • 11.2.12. Astellas Pharma Inc.
    • 11.2.13. F. Hoffmann-La Roche Ltd.
    • 11.2.14. Gilead Sciences Inc.
    • 11.2.15. Takeda Pharmaceutical Company Limited
    • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us